Home

Developing Therapeutic Treatments for Chronic Neuropathic Pain and Sensorineural Hearing Loss

Our Company


Hoba Therapeutic is an early-stage biotech based in Denmark developing innovative treatments for chronic pain disorders and sensorineural hearing loss - indications with a high unmet medical need for safe and efficacious treatments for millions of patients worldwide.

Science


Our science is based on the discovery of a novel family of endogenous human proteins: meteorin and cometin. These neurotrophic factors are involved in the development, growth, survival, and maintenance of nerve cells, supporting glial cells and sensory pathways.

Our Pipeline


Hoba Therapeutics holds the right to two novel biopharmaceutical drugs

  • HB-086 is in late preclinical development for neuropathic pain. The target indications are Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia.
  • HB-097 is in preclinical development for sensorineural hearing loss. The target indications are ototoxic and noise-induced hearing loss.


Latest News

11 December 2023

Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain



6 July 2022

 Eir Ventures, in partnership with the Danish Growth Fund, has completed an internal purchase of shares from Borean Innovation and is now an investor in Hoba Therapeutics.

14 October 2021

Hoba Therapeutics has been selected by The European Commission’s European Innovation Council (EIC) as a start-up champion. Hoba will receive grant funding and qualifies for further equity investment from EIC Accelerator.